Stock report · Delisted · Nasdaq
Bluebird bio Inc (BLUE)
4.97USD Delisted Final close · May 29, 2025
BLUE no longer trades. Bluebird bio was delisted from the Nasdaq in May 2025.
All prices on this page are historical. The last trade was on May 29, 2025, at $4.97.
BLUE stock price history
Final trading statistics
- Final close
- $4.97
- Final trading day
- May 29, 2025
- Market cap at delisting
- $48.67M
- Shares outstanding
- 9.79M
- Final 52-week range
- $0.29 – $10.28
- Avg. volume (final 3 mo.)
- 556,143
- All-time high
- $3017.28 · Mar 2018
- All-time low
- $3.29 · May 2025
- Return since IPO
- -98.6%
- Beta
- 0.36
- Book value / share
- −$5.91
- Price / book
- -0.84
About Bluebird bio Inc
bluebird bio was a U.S. biotechnology company that researched, developed and sold gene therapies for severe genetic diseases. Its products included ZYNTEGLO (betibeglogene autotemcel) for transfusion-dependent beta-thalassemia, LYFGENIA (lovotibeglogene autotemcel) for sickle cell disease with a history of vaso-occlusive events, and SKYSONA (elivaldogene autotemcel) for cerebral adrenoleukodystrophy.
Its clinical studies included HGB-205, HGB-206 and HGB-210 testing lovo-cel in sickle cell disease, and HGB-204, HGB-205, HGB-207 and HGB-212 testing beti-cel in beta-thalassemia.
Formerly Genetix Pharmaceuticals, it became bluebird bio in September 2010. The company was incorporated in 1992 and based in Somerville, Massachusetts, and was taken private as of May 29, 2025. Its shares were delisted from the Nasdaq in May 2025, with the last trade on May 29, 2025 at $4.97.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Somerville, MA
- Employees
- 248
- IPO date
- June 19, 2013
- Delisted
- May 29, 2025
- SEC CIK
- 1293971
Bluebird bio financials before the delisting
The last 5 fiscal years Bluebird bio reported as a public company, fiscal year ending December.
BLUE revenue and net income
BLUE earnings per share
BLUE annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $83.81M | −$240.7M | −$18.75 |
| FY2023 | $29.50M | −$211.9M | −$16.72 |
| FY2022 | $3.60M | −$266.6M | −$4.68 |
| FY2021 | $3.66M | −$562.6M | −$11.80 |
| FY2020 | $250.73M | −$618.7M | −$9.95 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Bluebird bio stock FAQ
What happened to Bluebird bio stock?
Bluebird bio was delisted from the Nasdaq in May 2025. The final close was $4.97 on May 29, 2025.
Can I still buy BLUE stock?
No. BLUE is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on May 29, 2025.
What was the last price of BLUE?
BLUE last closed at $4.97 on May 29, 2025, which valued the company at about $48.67M.
How did Bluebird bio do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Bluebird bio reported revenue of $83.81M and net income of −$240.7M.
When did Bluebird bio go public?
Bluebird bio shares started trading on June 19, 2013.
BLUE no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.